胸腔ドレナージカテーテルの世界市場-2023-2030

市場概要

胸腔ドレナージカテーテルの世界市場規模は、2022年に2億4,347万米ドル、2030年には3億6,975万米ドルに達すると推定され、予測期間（2023-2030年）にCAGR 5.5％で成長すると予測されています。

胸腔ドレナージカテーテルは、肺と胸壁の間にある胸膜腔に挿入するチューブで、溜まって呼吸困難を引き起こす余分な液体や空気を除去するために使用します。このチューブは通常、胸壁から挿入され、液体や空気を集めて体外に排出する排水システムに接続されています。胸腔ドレナージカテーテルは、手術後や外傷後、肺炎や肺がんなどの症状で使用されることが一般的です。

市場力学

技術の進歩、世界の自然気胸の負担増、胸部・心臓血管外科手術の増加、高齢者人口が胸腔ドレナージカテーテルの世界市場成長を促進します。

胸膜感染症患者の増加が市場成長の原動力となる

胸膜感染は、重症肺炎や治療が不十分な肺炎の二次感染として起こることがほとんどです。それでも最近、画像診断の進歩やCTスキャンの早期化によりか、実質的な感染を認めない一次性胸膜感染症が認められることが増えてきています。

2021年にJournal of Aspirationに掲載された論文の通り、胸膜疾患の発生率は上昇しており、英国（UK）だけで患者100万人あたり3000人と推定されています。胸膜腔に空気（気胸）や液体（胸水）が存在したり、良性、悪性、感染性のプロセスが発生したりすると、症状を緩和するための介入が必要となることが多いです。ドレナージは、小口径吸引キット（通常6または8フレンチゲージ）またはセルディンガー肋間ドレーン（ICD）の挿入で行うのが一般的です。

また、胸腔穿刺やICD挿入は侵襲的な処置であり、合併症のリスクは歴史的に高かったです。胸部超音波検査の普及により、誤挿入、ドレーンの位置ずれ、出血、感染、ドレーンの設置失敗、気胸、外科的気腫、再膨張性肺水腫、死亡などの合併症の発生率は減少しています。

胸腔ドレナージカテーテルに関連するリスクは、市場の成長を妨げるだろう

しかし、胸腔ドレナージカテーテルは一般的に安全とされていますが、その使用にはいくつかのリスクが伴います。体内にチューブを挿入する場合は、常に感染のリスクがあります。このリスクは、挿入部位を清潔にし、適切な滅菌手順を踏むことで最小化することができます。挿入部位で出血したり、カテーテルが血管を傷つけたりするリスクもわずかにあります。胸腔ドレナージカテーテルのリスクの1つは、気胸や肺の虚脱を引き起こす可能性があることです。このリスクは、カテーテルの挿入が不適切であったり、患者さんに肺の持病がある場合に高くなります。カテーテルが外れた場合、胸膜腔を効果的に排出することができなくなり、再挿入が必要になることがあります。

COVID-19影響度分析

COVID-19の流行が胸腔ドレナージカテーテル市場にプラスの影響を与えました。COVID-19のパンデミックは、胸部ドレナージカテーテル市場に大きな影響を与えています。呼吸器疾患の治療を必要とするCOVID-19患者の数が多いため、胸部ドレナージカテーテルの需要が増加し、一部の地域でこれらのデバイスが不足するようになりました。さらに、パンデミックによりサプライチェーンが乱れ、メーカーによる胸腔ドレナージカテーテルの生産・流通が困難になっています。パンデミックの進行に伴い、これらの機器の需要が増加し続けているため、市場は今後数年間で大きな成長を遂げると予想されます。

目次

第1章 市場の手法とスコープ

• 調査手法
• 調査目的および調査範囲について

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 胸部・心臓血管外科手術数の増加
    • 増加する自然気胸の有病率
  • 抑制要因
    • デバイスの高コスト
  • 機会
  • 影響度分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• レギュラトリー・アナリシス

第6章 COVID-19の分析

• 市場におけるCOVID-19の分析
  • COVID-19の市場シナリオの前に
  • 現在のCOVID-19の市場シナリオ
  • COVID-19以降または将来シナリオ
• COVID-19の中での価格・ダイナミクス
• 需給スペクトル
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• 結論

第7章 アプリケーション別

• 循環器内科
• 呼吸器科
• 一般集中治療・救急医療
• オンコロジー＆疼痛管理
• 感染症
• その他

第8章 エンドユーザー別

• 病院
• 外来診療所（Ambulatory Surgery Clinic
• その他

第9章 地域別

• 北米
  • タイプ
    • 米国
    • カナダ
    • メキシコ
• 欧州
  • ドイツ
  • U.K.
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢について

• 競合シナリオ
• 企業シェア分析
• 主な発展と戦略

第11章 企業プロファイル

• Medtronic
  • 会社概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Teleflex Incorporated
• Ply Gem Holdings Inc
• Smiths Group plc
• Medela AG
• ATMOS MedizinTechnik GmbH & Co. KG
• ARGON MEDICAL
• MAQUET Holding B.V. & Co. KG
• LivaNova PLC
• Cook

第12章 胸腔ドレナージカテーテルの世界市場-DataM

Market Overview

The global chest drainage catheter market size was valued at US$ 243.47 million in 2022 and is estimated to reach US$ 369.75 million by 2030, growing at a CAGR of 5.5% during the forecast period (2023-2030).

A chest drainage catheter is a tube inserted into the pleural space, the area between the lung and the chest wall, to remove excess fluid or air that can build up and cause difficulty breathing. The tube is typically inserted through the chest wall and is connected to a drainage system that collects the fluid or air and removes it from the body. Chest drainage catheters are commonly used after surgery, trauma, or in conditions such as pneumonia or lung cancer.

Market Dynamics

Technological advancements, the increasing burden of spontaneous pneumothorax across the globe, the rise in the number of thoracic & cardiovascular surgical procedures, and the geriatric population drive the global chest drainage catheter market growth.

An increasing number of pleural infection patients drive the market growth

Pleural infection most commonly occurs as a secondary infection in severe or undertreated pneumonia. Still, recently and increasingly, the primary pleural infection has been recognized without evidence of parenchymal infection, possibly due to advances in imaging and earlier computed tomography scanning.

As per the article published in the Journal of Aspiration in 2021, the incidence of the pleural disease is rising and is estimated to be 3000 per million patients in the United Kingdom (UK) alone. The presence of air (pneumothorax) or fluid (pleural effusion) in the pleural space or the development of benign, malignant or infective processes often necessitates intervention to relieve symptoms. Drainage is routinely performed with small bore aspiration kits (usually 6 or 8 French gauge) or insertion of a Seldinger intercostal drain (ICD).

In addition, thoracocentesis and ICD insertion are invasive procedures, and the risk of complications has historically been high. Widespread thoracic ultrasound use has reduced the incidence of complications, including incorrect placement, drain displacement, bleeding, infection, failure to place the drain, pneumothorax, surgical emphysema, re-expansion pulmonary edema and death.

The risk associated with chest drainage catheters will hamper the market's growth

However, chest drainage catheters are generally considered safe, but some risks are associated with their use. Any time a tube is inserted into the body, there is a risk of infection. This risk can be minimized by providing that the insertion site is clean and that proper sterilization procedures are followed. There is a small risk of bleeding at the insertion site or of the catheter causing injury to a blood vessel. One of the risks of a chest drainage catheter is that it may cause a pneumothorax or a collapsed lung. This risk increases if the catheter is inserted improperly or the patient has pre-existing lung conditions. If the catheter becomes dislodged, it can no longer effectively drain the pleural space and may require reinsertion.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the chest drainage catheter market. The COVID-19 pandemic has significantly impacted the chest drainage catheter market. The increased demand for chest drainage catheters due to the high number of COVID-19 patients requiring treatment for respiratory issues has led to a shortage of these devices in some areas. Additionally, the pandemic has caused disturbances in the supply chain, making it difficult for manufacturers to produce and distribute chest drainage catheters. The market is expected to see significant growth in the coming years as the demand for these devices continues to rise with the ongoing pandemic.

Segment Analysis

The pulmonology segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The pulmonology segment accounts for the highest market share. Primary spontaneous pneumothorax (PSP) is the spontaneous occurrence of air in the pleural space in patients without clinically apparent lung disease. The condition is associated with smoking.

As per the article published in BMC Pulmonary Medicine in 2020, recently, the pleural catheter or chest tube was commonly connected to an analog drainage system, in which air leakage is assessed by the observation of bubbling in the water seal.

In addition, digital drainage systems provide quantitative information on air leakage (flow) in mL/min, both actual and historical, thereby providing information on air leakage patterns. The ability to forecast extended air leakage following pulmonary resection through digital monitoring of air leakage patterns may allow for early intervention.

Geographical Analysis

North America region holds the largest market share of the global Chest Drainage Catheter market

North America dominates the market for chest drainage catheters and is expected to show a similar trend over the forecast period. Technological advancements, the rising prevalence of pulmonary and cardiac disease, and active regional players in the North American region drive the market.

According to Mayo Clinic, pleural infections remain a prevalent and difficult clinical issue. The incidence of pleural effusions is estimated to be 1.5 million new cases per year in the U.S. above both congestive heart failure and diabetes, which each see 1.8 million new cases each year (400,000 new diagnoses annually). An additional 40,000 people are affected by spontaneous and iatrogenic pneumothoraces.

In addition, ICU Medical offers Pleural Catheter with Flexible Introducer, the one-of-a-kind portex flexible introducer was created to comply with contemporary trauma and emergency treatment approaches for patients with chest injuries, which forbid the use of trocars to place drains. It meets the necessity to establish chest drainage quickly and poses no threat to the patient's internal health.

Competitive Landscape

The chest drainage catheter market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc., Smiths Group plc., Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the chest drainage catheter market globally.

Teleflex Incorporated

Overview:

Teleflex is a medical technology company designed to improve the health and quality of people's lives. The company provides a broad portfolio with solutions in vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.

Product Portfolio:

Pleur-evac Chest Drainage Systems: The Pleur-evac Chest Drainage System provides the premier chest drainage solution for thoracic, cardiovascular, trauma, and critical care, which uses the most advanced fluid management technology available.

The global chest drainage catheter market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Number of Thoracic & Cardiovascular Surgical Procedures
    • 4.1.1.2. Increasing Prevalence of Spontaneous Pneumothorax
  • 4.1.2. Restraints:
    • 4.1.2.1. High Cost of Devices
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Cardiology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
• 7.3. Pulmonology
• 7.4. General Intensive Care & Emergency Medicine
• 7.5. Oncology & Pain Management
• 7.6. Infectious Diseases
• 7.7. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
• 8.3. Ambulatory Surgery Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Company Share Analysis
• 10.3. Key Developments and Strategies
• 10.4.

11. Company Profiles

• 11.1. Medtronic*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Teleflex Incorporated
• 11.3. Ply Gem Holdings Inc
• 11.4. Smiths Group plc
• 11.5. Medela AG
• 11.6. ATMOS MedizinTechnik GmbH & Co. KG
• 11.7. ARGON MEDICAL
• 11.8. MAQUET Holding B.V. & Co. KG
• 11.9. LivaNova PLC
• 11.10. Cook

LIST NOT EXHAUSTIVE

12. Global Chest Drainage Catheter Market - DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us